Targeting DNA damage response in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cancer therapies like chemotherapy and radiotherapy induce DNA damage to kill cancer cells.
• The DNA damage response (DDR) machinery repairs DNA lesions, allowing cell survival.
• Cancer cells often possess unique DDR abnormalities not found in normal cells.

Purpose of the Study:

• To review strategies targeting cancer-specific DDR aberrations for improved therapeutic outcomes.
• To explore how DDR defects can serve as biomarkers for treatment response.
• To discuss the potential of inhibiting DDR pathways for monotherapy or combination treatment.

Main Methods:

• Review of preclinical and clinical studies evaluating DDR-targeting agents.
• Analysis of biomarkers associated with DDR pathway status.
• Examination of synthetic lethality principles in cancer therapy.

Main Results:

• Cancer-specific DDR abnormalities can be exploited as biomarkers and therapeutic targets.
• Inhibition of DDR pathways can sensitize cancer cells to DNA-damaging agents.
• Poly(ADP-ribose) polymerase (PARP) inhibitors demonstrate efficacy in homologous recombination-deficient cancers.

Conclusions:

• Targeting cancer-specific DDR aberrations represents a promising approach in oncology.
• DDR-targeted therapies offer potential for personalized cancer treatment and improved efficacy.
• Further evaluation in clinical trials is crucial for optimizing these novel treatment strategies.